# 20 Healthcare AI Companies Shaping Clinical Workflows in 2026
Intro
Healthcare AI entered 2026 with a different tone than the first wave of generative AI pilots. The market is no longer only about demos, note summaries, or broad claims that AI can reduce administrative burden. Buyers are now comparing production vendors, multi-year enterprise contracts, clinical validation, EHR integration depth, BAA coverage, FDA clearance where applicable, and whether a tool can survive the daily friction of care delivery.
The funding signals explain why the category deserves a market map. Abridge reached a reported $5.3 billion valuation after major 2025 financing. OpenEvidence became one of the most valuable healthcare AI companies after a 2026 Series D at a reported $12 billion valuation. Ambience Healthcare raised a large Series C in 2025 at a valuation above $1.2 billion. Tempus AI moved from private growth story to public company and reported more than $1.27 billion in FY25 revenue. Insilico Medicine raised a 2025 Series E and then listed on the Hong Kong Stock Exchange at the end of the year.
That capital does not make any one vendor the right answer for every healthcare organization. It does show that AI is moving into the operating budget for documentation, clinical knowledge retrieval, imaging triage, revenue cycle, pathology, patient engagement, and research.
This guide is written for healthcare executives, clinical operations leaders, CIOs, innovation teams, and practice owners who need a neutral way to read the market. Buying a vendor SaaS product is one valid path. Commissioning a custom build on HIPAA-Ready Architecture is another, especially when workflows are specific, data ownership matters, or several tools need to be stitched together. The goal is not to crown a winner. The goal is to make the category easier to evaluate.
How to read this list
The companies below are grouped by workflow category: ambient documentation, clinical reasoning and decision support, patient engagement and access, revenue cycle and practice operations, imaging AI, precision medicine and pathology, and drug discovery. Those categories matter because "healthcare AI" is too broad to evaluate as one market.
Each profile covers four practical questions: what the company does, what scale or funding signal makes it relevant in 2026, which buyer is likely to be the best fit, and what limitation or consideration should be reviewed before purchase. A limitation is not a criticism. In healthcare AI procurement, a poor fit is often just a mismatch between the vendor's strongest workflow and the buyer's actual operating need.
This is not a complete list of every useful healthcare AI company. It is a focused map of 20 companies that represent the main ways AI is entering clinical and operational workflows in 2026.
The 20 companies
Abridge
Abridge is one of the leading enterprise ambient documentation vendors for health systems. Its core product listens to clinical conversations, drafts structured notes, and helps clinicians finish documentation inside established EHR workflows. The company's funding profile became a major market signal in 2025, including a large Series E round and a reported valuation around $5.3 billion. Abridge is best fit for enterprise health systems that want a serious ambient scribe program across specialties and are prepared for change management, EHR integration, clinician onboarding, and governance. The main consideration is that large-system strength can also mean enterprise buying cycles and pricing structures that may not match a smaller independent clinic. Buyers should evaluate specialty coverage, note quality, downstream coding goals, and clinician review.
Microsoft Nuance Dragon Copilot
Microsoft Nuance Dragon Copilot launched in March 2025 by bringing together DAX Copilot and Dragon Medical One into a unified clinical workflow assistant. It combines dictation, ambient documentation, clinical information surfacing, and task automation inside the Microsoft healthcare ecosystem. Its scale signal is different from venture-backed startups: Nuance already had deep provider relationships, Dragon Medical One was widely used, and Microsoft can support enterprise procurement, security, and deployment. Dragon Copilot is best fit for large provider organizations that already trust Microsoft and Nuance, need enterprise contracting, and want documentation AI tied to a broader Microsoft environment. The main limitation is fit for buyers outside that enterprise motion. Smaller practices may find procurement and configuration more complex than lighter-weight scribe tools.
Ambience Healthcare
Ambience Healthcare provides ambient documentation, coding, and clinical documentation integrity support for health systems. Its July 2025 Series C of $243 million, with a valuation around $1.25 billion, positioned it as a major ambient AI vendor with ambitions beyond note drafting. Ambience is best fit for health systems that want documentation improvement connected to coding quality, CDI, and specialty-specific workflows rather than a standalone transcript-to-note tool. The consideration is implementation complexity. A platform that touches documentation, coding, and CDI needs clear ownership across clinical leadership, revenue cycle, compliance, and IT. Buyers should confirm which modules are mature for their specialties and whether the expected financial impact is measurable.
Suki AI
Suki AI is a voice assistant for clinical documentation, with products designed to help clinicians create notes, issue commands, and reduce time spent in the EHR. Its $70 million Series D in 2024 was a meaningful signal that ambient and voice documentation remained durable beyond the largest enterprise players. Suki can be a good fit for provider groups and health systems that want a voice-first documentation assistant with a focused user experience and support for multiple specialties. It may also appeal to organizations that want to improve individual clinician productivity without adopting a broader coding or operational platform. The main consideration is scope. If a buyer wants an end-to-end documentation, coding, CDI, and revenue cycle transformation program, Suki should be compared carefully against broader platforms.
Nabla
Nabla offers Ambient Copilot, a clinical documentation assistant with European roots and expanding US adoption. Its June 2025 Series C and reported use by roughly 85,000 clinicians across more than 130 healthcare organizations made it a notable ambient scribe competitor. Nabla is best fit for organizations that want a focused ambient documentation product with a broad clinician user base and product history outside the US-only enterprise market. It can be attractive for teams that value speed to deployment and a clean documentation workflow. The main consideration is buyer requirement depth. Health systems with highly specialized templates, complex inpatient workflows, or aggressive coding automation goals should test those needs directly. As with any scribe, note review, consent workflow, retention policy, and EHR transfer design matter.
OpenEvidence
OpenEvidence is an evidence-based clinical question-answering platform built for physicians and other healthcare professionals. Its 2026 Series D, reported at $250 million and a $12 billion valuation, made it one of the clearest funding signals in healthcare AI. The platform is best fit for clinicians who need fast, cited medical answers from trusted sources, and for organizations that want to standardize access to clinical evidence. The consideration is workflow boundary. OpenEvidence is a clinical knowledge and reasoning aid, not a replacement for physician judgment, local protocol, specialist consultation, or regulated medical device workflows. Buyers should evaluate source transparency, update cadence, specialty coverage, user verification, business model implications, and whether any PHI will be entered.
Regard
Regard focuses on diagnosis support and clinical reasoning inside the EHR. Rather than functioning primarily as a generic medical chatbot, it reviews patient data, surfaces potential diagnoses, and helps clinicians identify documentation or care gaps. Its July 2024 Series B is a signal of continued investor support for AI that works inside the clinical chart. Regard is best fit for hospitals and medical groups looking to improve diagnostic visibility, clinical documentation quality, and care team awareness using existing EHR data. The consideration is integration and governance. Tools that reason over chart data require strong data mapping, clinical validation, alert design, and review processes so they support clinicians without creating noise.
Glass Health
Glass Health offers AI-assisted diagnosis and clinical plan support for clinicians. It is most relevant as an early clinical reasoning assistant, useful for differential diagnosis thinking, plan structuring, and medical education style workflows. Compared with larger companies in this guide, Glass Health has smaller scale and earlier traction, so it should be evaluated as a focused clinical assistant rather than a mature enterprise platform. The best fit may be individual clinicians, training environments, or smaller teams exploring AI-assisted reasoning for non-emergent support. The main consideration is maturity. Healthcare organizations should be careful about using early clinical reasoning tools for high-stakes decisions without validation, policy, and clear accountability. Buyers should review evidence citation, uncertainty handling, input storage, and local governance fit.
Hippocratic AI
Hippocratic AI builds patient-facing generative AI agents for healthcare tasks such as scheduling, intake, outreach, chronic care support, and post-discharge follow-up. Its November 2025 Series C of $126 million at a reported $3.5 billion valuation made it a major signal for AI agents that interact directly with patients. Hippocratic AI is best fit for health systems, payers, and pharma organizations that need scalable, safety-focused agents for non-diagnostic patient communication. The main consideration is risk boundary design. Patient-facing AI needs strict escalation rules, identity checks, consent handling, content controls, monitoring, and human fallback. Buyers should be clear about which tasks the agent can perform, refuse, or escalate.
Notable
Notable automates patient access, scheduling, intake, and administrative workflows for health systems and medical groups. Its relevance comes from broad deployments across provider organizations and a product focus on reducing manual work around front-door operations. Notable is best fit for organizations with high patient access volume, fragmented scheduling steps, repeated outreach tasks, and staff capacity constraints. It is less about replacing a single clinical workflow and more about orchestrating administrative tasks across the patient journey. The main consideration is operational fit. Access automation touches call centers, scheduling rules, referral workflows, patient messaging, EHR data, and staff exception handling. A buyer should validate integration depth, rules flexibility, language support, and edge-case handling.
Commure
Commure, including Athelas and the Augmedix rollup, has positioned itself as a broader healthcare practice and enterprise operating platform spanning revenue cycle management, ambient AI clinical documentation, practice management, and workflow automation. Its June 2025 $200 million growth financing was a major signal for AI-enabled RCM and practice operations. Commure can be a good fit for provider groups, specialty clinics, and health systems that want one vendor across documentation, billing operations, and practice workflows. The consideration is breadth. A broad operating platform can simplify vendor management, but it also raises the stakes for implementation quality. Buyers should evaluate which parts are truly needed, how migration would work, and how performance will be measured.
Innovaccer
Innovaccer is a healthcare data platform company focused on unifying clinical, claims, patient engagement, population health, and operational data. Its January 2025 $275 million Series F, plus its presence across large health systems, made it a key platform signal for AI built on top of healthcare data infrastructure. Innovaccer is best fit for organizations that need a longitudinal data layer, value-based care tooling, population health workflows, CRM, analytics, and AI agents connected to enterprise data. The main consideration is that data platform projects are larger than point-tool purchases. Success depends on data quality, governance, integration scope, implementation capacity, and executive sponsorship. For a team that only needs a scribe or a scheduling bot, Innovaccer may be more platform than necessary. For a system modernizing its data foundation, it may be relevant.
Aidoc
Aidoc is an imaging AI platform focused on radiology triage, care coordination, and clinical workflow support. Its FDA clearance for a foundation model-powered triage solution signaled that imaging AI is moving from single-condition algorithms toward broader platform approaches. Aidoc is best fit for hospitals and radiology groups that need to prioritize acute findings, coordinate downstream care, and reduce delay in imaging-heavy workflows. The main consideration is regulated workflow fit. Imaging AI buyers need to review FDA clearance scope, indication coverage, PACS and EHR integration, radiologist workflow impact, false positive and false negative handling, and clinical escalation protocols. Aidoc can be valuable where imaging volumes and care coordination needs are high, but one clearance or module will not cover every modality or condition.
Viz.ai
Viz.ai combines AI-powered disease detection with care coordination, especially in stroke and other time-sensitive conditions. Its reported footprint of nearly 2,000 hospitals and January 2026 announcement of profitability in its healthcare business made it one of the more scaled imaging and coordination platforms. Viz.ai is best fit for health systems that want to connect detection, team notification, and specialist coordination for acute pathways. Its strongest fit is not simply image interpretation, but operational response when minutes matter. The main consideration is pathway specificity. Buyers should map exactly which service lines are in scope, who receives alerts, how false positives are handled, and whether the tool improves door-to-treatment or transfer metrics. Viz.ai may be less relevant for organizations that only need general radiology productivity support without a coordinated care pathway.
Cleerly
Cleerly applies AI to cardiovascular CT analysis, helping clinicians assess coronary artery disease and plaque characteristics from CCTA imaging. Its December 2024 $106 million Series C extension supported commercial growth and clinical evidence generation. Cleerly is best fit for cardiology groups, imaging centers, and health systems building advanced coronary care pathways around non-invasive imaging. The consideration is that Cleerly's value depends on the organization's cardiovascular strategy, imaging volume, referral patterns, and reimbursement environment. It is not a broad hospital AI platform. It is a specialized tool for heart disease evaluation and prevention workflows. Buyers should review FDA-cleared use, clinical evidence, reporting workflow, cardiologist adoption, and how results influence treatment decisions. For the right cardiovascular program, specialization can be a strength. For unrelated workflows, it will not be the right category.
Tempus AI
Tempus AI provides AI-enabled precision medicine, genomics, data, and oncology workflow tools. It went public in 2024 and reported FY25 revenue of approximately $1.27 billion, making it one of the most visible public healthcare AI companies. In August 2025, Tempus acquired Paige for $81.25 million, bringing digital pathology assets, pathology AI, and a large slide dataset into its oncology strategy. Tempus is best fit for oncology programs, life sciences teams, and organizations that need genomic testing, multimodal data, clinical trial matching, and precision medicine infrastructure. The main consideration is scope and economics. Tempus is not a generic AI assistant or simple workflow automation tool. Buyers should evaluate test utilization, data rights, oncology workflow integration, payer dynamics, and pathology roadmap.
PathAI
PathAI develops AI-powered digital pathology technology for laboratories, pharma, clinical trials, and diagnostic workflows. Its partnerships with laboratories, biopharma organizations, Roche Tissue Diagnostics, Discovery Life Sciences, Precision for Medicine, and Labcorp show its role in pathology infrastructure rather than general clinical productivity. PathAI is best fit for pathology labs, life sciences companies, and health systems moving toward digital pathology workflows with AI-enabled image management, biomarker analysis, quality support, and research applications. The main consideration is readiness for digital pathology. Organizations need slide scanning infrastructure, lab workflow redesign, storage planning, pathologist adoption, validation, and regulatory review. PathAI is less relevant for buyers seeking near-term administrative automation or a general clinical assistant.
Recursion
Recursion is an AI-driven drug discovery company using large biological and chemical datasets, automated experimentation, and machine learning to industrialize parts of discovery and development. Its 2024 combination with Exscientia brought together Recursion's scaled biology platform and Exscientia's AI-driven chemistry and small molecule design capabilities. Recursion is best fit for investors, pharma partners, and biotech stakeholders evaluating AI-native drug pipelines and platform partnerships. It is not a provider workflow vendor, so hospitals and clinics should not evaluate it alongside scribes, scheduling tools, or EHR copilots. The main consideration is the long evidence cycle of drug development. AI can change target discovery, molecule design, and experimentation speed, but clinical success still depends on safety, efficacy, trial execution, regulatory review, and commercial strategy. The signal is strategic, not immediate clinical operations impact.
Insilico Medicine
Insilico Medicine is an end-to-end generative AI drug discovery company using AI for target discovery, small molecule design, development planning, and automated lab work. It raised a $110 million Series E in 2025 and listed on the Hong Kong Stock Exchange in December 2025, creating a public-market signal for AI-driven biotech. Insilico is best fit for pharma, biotech, and research stakeholders interested in AI-native discovery platforms and pipelines, including drug candidates such as its work in idiopathic pulmonary fibrosis. The main consideration is the same one that applies across AI drug discovery: platform capability and clinical outcome are not identical. Buyers and partners should distinguish between faster discovery workflows, preclinical progress, clinical trial evidence, and approved therapies. Insilico belongs in a healthcare AI market map because it shapes R&D, not because it changes day-to-day clinic operations.
Owkin
Owkin applies AI to biology, pathology, multimodal patient data, federated learning, and life sciences research. The company has raised about $300 million and, in January 2026, announced an Anthropic Claude for Healthcare and Life Sciences collaboration that made its Pathology Explorer agent accessible through modern AI workflows. Owkin is best fit for pharma, research networks, hospitals, and life sciences teams that need privacy-aware learning across distributed data and specialized biological copilots. The main consideration is partnership complexity. Federated learning and multimodal research AI require strong data agreements, institutional trust, scientific validation, and implementation support. Owkin is not a plug-and-play clinical operations tool for a small practice. It is more relevant where research, pathology, real-world data, and drug development questions intersect, especially when data cannot simply be centralized.
How to evaluate in 2026
- BAA and HIPAA posture: Confirm whether the exact product, tier, workflow, and data flow are covered by a signed BAA. Do not rely on a generic "HIPAA compliant" claim.
- EHR integration: Ask whether the vendor writes into the EHR, reads from it, launches inside it, or only copies text into it. Those differences affect adoption and risk.
- Clinical validation and FDA clearance: For imaging, diagnostics, and clinical decision support, review the exact clearance, indication, study population, and intended use. For non-device workflows, review customer evidence and quality monitoring.
- Unit economics and pricing: Compare seat pricing, encounter pricing, implementation fees, minimum commitments, usage-based charges, and expected ROI. A tool that saves time can still be a poor fit if incentives are misaligned.
- Workflow customization: Healthcare workflows vary by specialty, location, payer mix, and staffing model. Evaluate how much configuration is available without turning the deployment into a custom project anyway.
- Data portability: Confirm export rights, audit logs, retention rules, model training exclusions, and what happens if the contract ends.
- Vendor stability and funding runway: Funding is not a guarantee, but it affects hiring, support, roadmap execution, and acquisition risk. Public-company financials, profitability claims, and strategic backing all deserve review.
- Partnership model: Decide whether you need a product vendor, a platform partner, an implementation partner, or a custom build team. Many failed projects start with the wrong partnership model, not the wrong model.
When to buy a platform vs commission a custom build
Off-the-shelf SaaS is often the right choice when the workflow is standard, the vendor already supports your EHR, and the roadmap matches your buyer fit. Ambient documentation, imaging triage, cardiovascular CT analysis, patient scheduling, and some revenue cycle workflows are mature enough that a specialized vendor may be faster than building from scratch.
A custom build becomes more attractive when the workflow is specific to your operation. That might mean specialty-specific intake, multi-location referral routing, payer-specific prior authorization logic, custom quality review, internal policy search, or a blended workflow that touches several systems. It also makes sense when your organization needs to own the data layer, retain control of prompts and outputs, or deploy on Azure OpenAI, AWS Bedrock, or Google Vertex under existing BAAs.
Custom HIPAA-Ready Architecture is also relevant when the challenge is not one task, but orchestration. A clinic might use one scribe, a separate RCM tool, a patient messaging system, a document repository, and a BI platform. If no single vendor owns the whole process, a custom agent layer can provide the workflow glue, audit trail, and governance model.
CloudNSite's role in that scenario is not to replace every vendor. It is to help teams decide where SaaS is enough and where a purpose-built system is more responsible. See our custom AI build approach, custom agents, and HIPAA compliant AI pages for the architecture lens.
FAQ
What is the biggest healthcare AI company in 2026?
It depends on how "biggest" is defined. Microsoft is the largest company in this guide by overall enterprise scale. Among healthcare AI-focused companies, OpenEvidence has one of the highest reported private valuations, while Tempus AI is a major public healthcare AI company by revenue.
Which healthcare AI companies have a BAA?
Many enterprise healthcare vendors offer BAAs, but coverage depends on product, contract, deployment, and data flow. Microsoft Nuance, major cloud platforms, and healthcare-specific vendors often have BAA paths. Always verify the exact scope. See our HIPAA compliant AI tools guide.
Are ambient AI scribes HIPAA compliant?
They can be appropriate for HIPAA-regulated use when the vendor signs a BAA, the workflow is configured correctly, and retention, access, consent, and EHR handling are governed. A scribe is not automatically compliant because it serves healthcare.
How do I compare Abridge vs Ambience vs Suki vs Nuance Dragon Copilot?
Start with workflow fit. Abridge is often evaluated for enterprise ambient documentation. Ambience adds coding and CDI emphasis. Suki is a focused voice and documentation assistant. Dragon Copilot fits organizations already aligned with Microsoft and Nuance.
What is the best healthcare AI company for a small clinic?
The best fit is usually the tool with the shortest path to value, manageable pricing, clear BAA terms, and low implementation burden. A small clinic may prefer a focused scribe or scheduling tool over a broad enterprise platform.
When does a custom build beat a vendor?
A custom build can be the better fit when the workflow is unique, the data layer must stay under your control, or multiple tools need one governed orchestration layer. For PHI workflows, use HIPAA-Ready Architecture rather than an ad hoc app.
How are healthcare AI vendors funded in 2026?
Funding ranges from venture-backed private rounds to public-market revenue and strategic partnerships. Large rounds in ambient documentation, clinical Q&A, patient agents, and AI drug discovery show investor interest, but buyers should still evaluate implementation fit.
Can my team use ChatGPT with patient data?
Do not put PHI into consumer ChatGPT. Healthcare use requires the right product path, contract, BAA where applicable, retention controls, and governance. See Is ChatGPT HIPAA compliant? for a detailed breakdown.
CTA
If you are evaluating any of these vendors and want a neutral architecture review, CloudNSite builds HIPAA-Ready Architecture on Azure, AWS, and Google Cloud under existing BAAs. We help healthcare teams decide where a vendor SaaS product is enough, where custom workflow automation makes sense, and how to keep PHI handling governed from the start.
See our custom AI build approach or HIPAA compliant AI solution. For a practical procurement starting point, use the HIPAA AI checklist.